BUND FINANCE

BUND FINANCE › Stocks › DXCM

DexCom, Inc. (DXCM)

NASDAQ · Stock price, chart and technical analysis

US$80.19-2.33 (-2.82%)

Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$82.52
OpenUS$82.50
Day rangeUS$79.19 – US$82.76
52-week rangeUS$56.72 – US$92.59
Market capUS$29.91B
Volume4.47M
50-day averageUS$84.10
200-day averageUS$75.22
Beta1.44

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$2.4BUS$2.9BUS$3.6BUS$4.0BUS$4.7B
Net incomeUS$216.9MUS$341.2MUS$541.5MUS$576.2MUS$836.3M
EPS (diluted)0.530.821.301.422.09
Gross margin68.6%64.7%63.2%60.5%60.1%
Operating margin10.9%13.4%16.5%14.9%19.6%
Net margin8.9%11.7%15.0%14.3%17.9%
Free cash flowUS$53.3MUS$304.7MUS$511.9MUS$630.7MUS$1.1B
Total debtUS$2.2BUS$2.1BUS$2.6BUS$2.6BUS$1.4B
CashUS$1.1BUS$642.3MUS$566.3MUS$606.1MUS$917.7M

Compound annual growth: revenue 17.5% · net income 40.1% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E31.5x107.8x26.4x
EV / EBITDA19.0x66.1x16.3x
Operating margin24.0%—3.6%
Net margin19.4%—-0.0%
Debt / equity1.46—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About DexCom, Inc.

SectorHealthcare
IndustryMedical - Devices
CountryUS
CEOJacob Steven Leach
Employees11,050
IPO date2005-04-14

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring plat…

www.dexcom.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice